|
|
|
|
|
|
|
Company’s Placental Stem Cells Show Potential In Treating Autoimmune Disorders
Tuesday, November 27, 2007
- Stem Cell Business News |
|
|
|
|
|
|
New York, N.Y.-based Pluristem Therapeutics, Inc. (PSTI), said on November 27 that in vitro testing of its placenta-derived stem cells cells demonstrated the potential to treat autoimmune disorders.
The company said testing showed a significant reduction of TNF-alpha and interferon-gamma inflammatory cytokines that are known to be involved in the pathogenesis of autoimmune disorders.
Reducing TNF-alpha and interferon-gamma is considered a key factor in mitigating the symptoms of autoimmune disorders, such as multiple sclerosis, rheumatoid arthritis, Crohn’s disease and juvenile or type 1 diabetes.
“The strong anti-inflammatory results show that our PLX cells may have the capability to help millions of patients and represent an additional potential multi-billion dollar market for our PLX cells,” said CEO Zami Aberman. “These impressive results suggest that our 3D-expanded placental cells could become an allogeneic, non-controversial source for stem cell therapeutics in the future.”
Pluristem is dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders.
Pluristem’s products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta.
They are expanded in the company’s proprietary bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials.
Contact: http://www.pluristem.com
Scroll down to see related articles below.
|
|
Related
Articles :
- Company’s Cell Therapy Product Boosts Cord Blood Engraftment (Monday, October 16, 2006)
A Haifa, Israel-based firm said it has achieved promising final results of an animal model study of an adjuvant cell therapy product based on placenta expanded mesenchymal cells.
- Company Finds Evidence Its Mesenchymal Stem Cells Are “Immune Privileged” (Wednesday, January 31, 2007)
Pluristem Life Systems, Inc. (PLRS), on January 29 said it has found evidence that its mesenchymal stem cells have proven to be “immune privileged,” meaning that there is less or no rejection when the cells implanted.
- FDA Accepts Pluristem’s Pre-IND Application To Study Blood Cancers (Thursday, February 08, 2007)
Pluristem Life Systems, Inc. said the U.S. FDA’s Center for Biological Evaluation and Research (CBER) accepted the company’s proposed pre-investigation new drug (PreIND) for its PLX-I product in pre-clinical studies for treating blood cancers.
- Pluristem, Stem Cell Innovations Seal Licensing, Stock Swap Deal (Thursday, February 22, 2007)
Pluristem Life Systems has completed a licensing agreement and stock swap with Stem Cell Innovations for marketing rights of Pluristem’s PLX I product in Asia, excluding Japan in exchange for an upfront fee of stock and other considerations.
- Company Cites Evidence That Its Stem Cells Are Immunosuppressive (Thursday, March 01, 2007)
Pluristem Life Systems has evidence that its proprietary mesenchymal stem cells are immunosuppressive and immune privileged.
- Pluristem Acquires Patents, Technology For 3-D Expansion Of Human Cells (Tuesday, May 22, 2007)
Pluristem Life Systems has purchased patents for its innovative stem cell production technology from the Technion-Israel Institute of Technology and the Weizmann Institute of Science.
- Company's Stem Cells Show Potential to Treat Parkinson's (Thursday, June 14, 2007)
Pluristem Life Systems said that studies have shown that its PLacenta eXpanded (PLX) cells have properties in vitro that give the cells the potential to treat Parkinson's disease.
- Study Using Pluristem Cells Shows Promise As Treatment For Stroke (Thursday, October 18, 2007)
Results from a German study using Pluristem’s PLacenta eXpanded (PLX) cells in treating ischemic stroke showed initial promise as a stroke therapy.
|
|
|
|
|
|
|
|
| |
|
 |
|
|
|
|
 |
